[verwijderd] 31 oktober 2016 19:56 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:omaneus schreef op 31 oktober 2016 18:34:[...]ik heb het zeker al onderbouwd. Het sentiment zit nu ook niet mee gezien de olieprijs onderhandelingen.Daarom verwacht ik dus nu geen 9 euro maar 8 euroNiet overdrijven. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 31 oktober 2016 20:11 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:JacobusJW schreef op 31 oktober 2016 19:56:[...]"Archief, historische posities...." downloaden.Linksonder op "current positions" klikken.Daarna bovenin op driehoekje "full issuer name" en Fagron kiezen.dan zie je de actuele short. Aanbevelingen 0 ” Quote Reageren Niet oké
Machiavelli 31 oktober 2016 20:13 auteur info Machiavelli Lid sinds: 10 okt 2016 Laatste bezoek: 18 apr 2024 Aanbevelingen Ontvangen: 1273 Gegeven: 2957 Aantal posts: 2.987 shortsell.nl/short/FagronLink werkt niet...Fagron4,23% short Aanbevelingen 0 ” Quote Reageren Niet oké
Azoia 31 oktober 2016 23:03 auteur info Azoia Lid sinds: 12 sep 2016 Laatste bezoek: 17 apr 2024 Aanbevelingen Ontvangen: 16 Gegeven: 61 Aantal posts: 180 FTSE slips, though posts fifth straight month of gains share with twitter share with LinkedIn share with facebook share via e-mail 010/31/2016 | 05:57pm CETA red London bus passes the Stock Exchange in LondonBritain's top share index retreated on Monday but posted a fifth straight month of gains, as advertising group WPP rose after reporting its third-quarter results.The blue chip FTSE 100 <.FTSE> index was down 0.6 percent at 6,954.22 points by the close, but up 0.8 percent for October.Shares in WPP (>> WPP PLC) rose 4 percent and posted their biggest daily gain in four months. WPP, the world's largest advertising group, reported results in line with expectations."We are encouraged by the positive nature of this morning’s update and remain fundamentally positive on WPP’s ability to capitalise on a solid medium-term outlook for global advertising spend," Roddy Davidson, an analyst at Shore Capital Markets, said in a note.However, investors were less optimistic about some forthcoming earnings. The top fallers were Shire (>> Shire PLC), which reports results on Tuesday, and Next (>> NEXT plc), whose results are due on Wednesday, down 2.8 percent and 3.2 percent respectively.The FTSE 100 index posted a fifth month of gains in a row for the first time since early 2013. The index has been buoyed by a rally in banks and mining companies.Banks were boosted by last week's well-received earnings from Barclays (>> Barclays PLC) and Lloyds (>> Lloyds Banking Group PLC), with the FTSE 350 banking sector <.FTNMX8350> hitting its highest level for the year.October saw the FTSE 100 set a record high of 7,129.83 points. A weaker pound has bolstered the index, which has rallied about 10 percent since Britain voted in June to leave the European Union. The cheaper pound helps the index's international, dollar-earning firms.Some analysts, however, were more cautious on the outlook for British shares."(The FTSE) is still continuing the positive run of gains since Brexit, so it's a Brexit bounce. But it's run into that previous record high ... and pulled back quite significantly from there," said Jasper Lawler, market analyst at CMC Markets.Investors, he added, were holding back before upcoming central bank interest rate decisions and the U.S. presidential election on Nov. 8."I think no one's really got the confidence to buy the market up through into new record highs."The more domestically exposed FTSE 250 index <.FTMC> fell 0.6 percent, and was down 1.8 percent for the month of October. It has been weighed down by a spate of profit warnings and big declines from companies including Berendsen (>> Berendsen PLC), Cobham (>> Cobham plc), Senior (>> Senior plc) and Keller (>> Keller Group plc).(Editing by Mark Heinrich) Aanbevelingen 0 ” Quote Reageren Niet oké
Azoia 31 oktober 2016 23:04 auteur info Azoia Lid sinds: 12 sep 2016 Laatste bezoek: 17 apr 2024 Aanbevelingen Ontvangen: 16 Gegeven: 61 Aantal posts: 180 Canada drugmaker Cipher mulls sale - sources share with twitter share with LinkedIn share with facebook share via e-mail 010/31/2016 | 08:25pm CETCipher Pharmaceuticals Inc (>> Cipher Pharmaceuticals Inc), a Canadian specialty pharmaceuticals manufacturer, has hired an investment bank to review strategic alternatives, including a potential sale, people familiar with the matter said.Cipher Pharmaceuticals Inc (>> Cipher Pharmaceuticals Inc), a Canadian specialty pharmaceuticals manufacturer, has hired an investment bank to review strategic alternatives, including a potential sale, people familiar with the matter said.The strategic review comes amid increased U.S. scrutiny of specialty drug prices, which has weighed on the valuations of many Canadian specialty pharmaceutical companies with U.S. revenues.There is no certainty that a sale of Cipher will occur, the people cautioned, asking not to be identified because the deliberations are confidential.Shares of Cipher shot up as much as 22 percent after the Reuters report. They were up 8.3 percent on Monday afternoon in Toronto."The company is working with an advisor to consider various strategic alternatives potentially available to enhance shareholder value, with a focus on the U.S. business," Cipher said in a press statement following the report.Toronto, Ontario-based Cipher, which has a market capitalization of $89.5 million, specializes in treatments for skin disorders. Its products include Nuvail, a topical film that treats fragile nails, and Bionect, which treats skin irritations. It has about $35 million in debt, according to regulatory filings.Cipher shares have dropped more than 70 percent from 2015 highs amid a broader pullback in the specialty pharmaceutical sector that has also impacted shares of Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc) and Concordia International Corp (>> Concordia International Corp).Concordia explored strategic alternatives earlier this year, before opting to improve liquidity by raising debt. Valeant has said it plans to sell about $8 billion in assets to help pay down its $30 billion debt pile.Cipher has been in the spotlight since its largest shareholder, John Mull, in July published a letter calling for the company's board to consider trimming its size, replacing some members of the management team and reviewing its business model. He did not call on the company to sell itself.In August, the board reconstituted itself, with four board members stepping down and three joining. Last month, Mull, who owns nearly 40 percent of the company, was appointed chair of the board of directors and Stephen Lemieux took over from Norman Evans as chief financial officer.Last year, Cipher acquired dermatology company Innocutis Holdings LLC for $45 million. In May, it bought the rights to a tattoo removal cream from Dalhousie University in Nova Scotia.(Reporting by Carl O'Donnell in New York and John Tilak in Toronto; Editing by Meredith Mazzilli, Bernard Orr)By Carl O'Donnell and John Tilak Aanbevelingen 0 ” Quote Reageren Niet oké
Azoia 31 oktober 2016 23:05 auteur info Azoia Lid sinds: 12 sep 2016 Laatste bezoek: 17 apr 2024 Aanbevelingen Ontvangen: 16 Gegeven: 61 Aantal posts: 180 Valeant Pharmaceuticals Intl : Shares Down on Bloomberg Report of Criminal Probe of Accounting share with twitter share with LinkedIn share with facebook share via e-mail 010/31/2016 | 09:09pm CETFederal prosecutors are looking into possible accounting-fraud charges against Valeant Pharmaceuticals International Inc. (>> Valeant Pharmaceuticals Intl Inc), Bloomberg News reported Monday, citing people familiar with the matter.Charges are possible within weeks, but no charging decisions have been made, Bloomberg reported.Valeant told Bloomberg "we are in frequent contact and continue to cooperate" with authorities.Valeant shares recently traded down 8.5% to $18.62.Full story at www.bloomberg.com/news/articles/2016-...Write to nymonitoring@dowjones.com Aanbevelingen 0 ” Quote Reageren Niet oké
Machiavelli 1 november 2016 09:00 auteur info Machiavelli Lid sinds: 10 okt 2016 Laatste bezoek: 18 apr 2024 Aanbevelingen Ontvangen: 1273 Gegeven: 2957 Aantal posts: 2.987 www.iex.nl/Forum/Topic/1339580/Fagron... Aanbevelingen 0 ” Quote Reageren Niet oké
Beursgoeroe 1 november 2016 10:18 auteur info Beursgoeroe Lid sinds: 09 apr 2002 Laatste bezoek: 17 sep 2023 Aanbevelingen Ontvangen: 2055 Gegeven: 2 Aantal posts: 7.975 quote:JacobusJW schreef op 31 oktober 2016 19:56:[...]Niet overdrijven.koersdoel is toch € 15,00 ? ... Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 1 november 2016 17:55 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:JacobusJW schreef op 31 oktober 2016 19:51:[...]De Belgische FSMA heeft vandaag de shortposities weereens niet bijgewerkt.De Belgische FSMA heeft vandaag de shortposities weereens niet bijgewerkt. De stand per afgelopen donderdag is 1,79% oftewel ca 1,3 miljoen aandelen. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 1 november 2016 18:32 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:1 2 3 schreef op 1 november 2016 10:18:[...]koersdoel is toch € 15,00 ? ...De koersdoelen liggen tussen 8€ en 15€. Aanbevelingen 0 ” Quote Reageren Niet oké
MVo_ 2 november 2016 08:56 auteur info MVo_ Lid sinds: 20 nov 2006 Laatste bezoek: 21 jul 2022 Aanbevelingen Ontvangen: 71 Gegeven: 109 Aantal posts: 696 Dat kan dus betekenen dat de Shorters er erg langzaam (of niet) uit gaan. Wees dus op je hoede! Daarnaast daalt mijn inziens de koers omdat het momentum even weg is. Komt wel weer terug! Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 2 november 2016 18:07 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 De shortposities zijn tot en met maandag ongewijzigd. Het blijft bij 1,79%.Nu maar hopen dat Clinton verliest want dat komt de biotech ten goede.En dan....dan moeten ZE met spoed minimaal 1,3 miljoen aandelen coveren.;-) Aanbevelingen 0 ” Quote Reageren Niet oké
Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re) EU aandelen NAV Investment Funds (NAV) Noord-Amerika NYS New York Stock Exchange OTC CBOE BZX Exchange (US) TSE Toronto Stock Exchange Kunt u een instrument niet vinden? Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code. Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze. Waar vind ik die ISIN code? Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'. Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.